Q-omics provides the consensus-scored TMEM42 profile across patient tissues and cancer cell-line models. TMEM42 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM42 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TMEM42 RNA expression shows 18,511 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where TMEM42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM42 survival associations across molecular data types. TMEM42 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM42 RNA expression–survival associations across cancer types. High TMEM42 expression shows unfavorable associations in KIRC, LIHC and KICH, but favorable associations in KIRP, READ and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM42 RNA expression.
This table summarizes TMEM42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM42 shows lower tumor expression in KIRC, KICH and LUSC and higher tumor expression in COAD, LIHC and BLCA. The COAD box plot shows higher TMEM42 RNA expression in tumor versus normal tissue (log2 FC = +0.582, t-test p < 0.001).
This table shows molecular features associated with TMEM42 in patient tissues and cancer cell lines. In patient samples, TMEM42 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
